[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354101-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354101-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","survival-outcomes-and-treatment-patterns-in-primary-vertebral-diffuse-large-b-cell-lymphoma","Survival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma","","Primary vertebral diffuse large B-cell lymphoma (PV-DLBCL) is a rare extranodal non-Hodgkin lymphoma subtype with nonspecific presentation and difficult diagnostic and treatment decisions. Using the SEER database (2000–2021), 584 adult patients with histologically confirmed PV-DLBCL were analyzed with demographic, tumor, and treatment variables. Overall survival was estimated with Kaplan-Meier methods and mortality predictors were assessed using Cox models. Median OS was 115 months; chemotherapy improved survival at all time points, while surgery and radiotherapy showed no independent benefit after adjustment. Age, distant stage, and marital status predicted higher mortality.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/survival-outcomes-and-treatment-patterns-in-primary-vertebral-diffuse-large-b-cell-lymphoma/354101/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/survival-outcomes-and-treatment-patterns-in-primary-vertebral-diffuse-large-b-cell-lymphoma/354101.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was overall survival estimated for PV-DLBCL patients in this study?","Question",{"text":63,"@type":64},"Overall survival was estimated using Kaplan-Meier analysis across multiple time horizons (1, 2, 5, and 10 years).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which factors were independently associated with higher mortality?",{"text":68,"@type":64},"Increasing age, distant tumor stage, and being unmarried (single, widowed, or divorced) were independently associated with higher mortality.",{"name":70,"@type":61,"acceptedAnswer":71},"Did surgery or radiotherapy improve survival compared with chemotherapy?",{"text":72,"@type":64},"After multivariable adjustment, neither radiotherapy nor surgery conferred an independent survival benefit, while chemotherapy was associated with significantly improved survival at all time points.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354101,1790158559,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSurvival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma  \nNicholas Bever􀀍, Ali Ebada, Christopher J. Carron, Jose E. Marin Sanchez & Salah G. Aoun  \nPrimary vertebral diffuse large B-cell lymphoma (PV-DLBCL) is a rare manifestation of extranodal non-Hodgkin lymphoma that presents with nonspecific symptoms and poses significant diagnostic and treatment challenges. While chemotherapy, radiation, and surgery are frequently employed, their relative impacts on long-term survival remain unclear. Using the SEER database (2000–2021), we identified 584 adult patients with histologically confirmed PV-DLBCL. Demographic, tumor, and treatment characteristics were analyzed. Cox proportional hazards models were used to evaluate predictors of mortality, and Kaplan-Meier analysis was performed to estimate overall survival. The median overall survival (OS) was 115 months. The 1-, 2-, 5-, and 10-year OS rates were 74.9%, 70.2%, 61.9%, and 49.3%, respectively. Increasing age, distant tumor stage, and unmarried status (single, widowed, or divorced) were independently associated with higher mortality. Chemotherapy was associated with significantly improved survival across all time points. By contrast, neither radiotherapy nor surgery conferred a survival benefit after multivariable adjustment. Patients diagnosed more recently (2013–2021) demonstrated lower mortality. In this population-based study of PV-DLBCL, chemotherapy emerged as the strongest predictor of improved survival. The lack of independent survival benefit from surgery or radiation underscores the need to reevaluate their routine use. Additionally, the association between marital status and survival highlights the importance of psychosocial factors in patient care. These findings inform treatment planning and support ongoing efforts to optimize care in this rare spinal lymphoma subtype.  \nKeywords Spine, Diffuse large B-cell lymphoma, Primary vertebral lymphoma, SEER database, Chemotherapy  \nNon-Hodgkin lymphoma (NHL) is among the most common cancers in the United States, accounting for nearly 4% of all cancer diagnoses1. Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype, comprising approximately 30% of NHL cases2. Although DLBCL typically originates in lymph nodes, extranodal involvement is frequent and often confers a worse prognosis, with multiple studies reporting reduced overall survival (OS) in these patients3,4. The vertebral column represents a rare but clinically important site for patients with DLBCL, given the unique diagnostic and therapeutic challenges they pose.  \nPrimary vertebral DLBCL (PV-DLBCL) is typically not characterized by specific clinical manifestations in the early stage, with many patients reporting no obvious B symptoms or lymphadenopathy5–7. Instead, patients may present with nonspecific symptoms like back pain, radiculopathy, mechanical instability, or spinal cord compression5,7,8. These nonspecific presentations, combined with the absence of characteristic imaging findings, increase the risk of misdiagnosis, treatment delays, and irreversible neurological deficits9, 10.  \nBecause PV-DLBCL can cause rapid neurological decline, prompt diagnosis and coordinated treatment—often involving surgery, chemotherapy, and radiotherapy—are essential to prevent irreversible deficits, improve quality of life, and optimize survival. However, much of the current literature10–15 on spinal DLBCL is limited to case reports and small series, leaving gaps in understanding of its epidemiology, treatment approaches, and long-term survival outcomes.  \nThe primary aim of this study is to evaluate overall survival and clinical predictors in PV-DLBCL, with specific emphasis on the association of chemotherapy, surgery, and radiotherapy with outcomes in a large, national cohort. By characterizing survival outcomes in a national cohort, this study aims ","cbCaiv9OHPQejmma","https://ap.wps.com/l/cbCaiv9OHPQejmma","pdf",1543428,"English","# Methods\n## Study population\n## Patient demographics and variables\n## Statistical analysis","[{\"question\":\"How was overall survival estimated for PV-DLBCL patients in this study?\",\"answer\":\"Overall survival was estimated using Kaplan-Meier analysis across multiple time horizons (1, 2, 5, and 10 years).\"},{\"question\":\"Which factors were independently associated with higher mortality?\",\"answer\":\"Increasing age, distant tumor stage, and being unmarried (single, widowed, or divorced) were independently associated with higher mortality.\"},{\"question\":\"Did surgery or radiotherapy improve survival compared with chemotherapy?\",\"answer\":\"After multivariable adjustment, neither radiotherapy nor surgery conferred an independent survival benefit, while chemotherapy was associated with significantly improved survival at all time points.\"}]","Survival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma | PDF",1790108927,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3909047621b8d6f233f52768bb537406.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4af150dcba79c035344574177210b1fd.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72eead3816aaed880f0f72c67bc06ab0.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e6ce69cb033d7b051423c3d558de568.webp",980,1287]